Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 31-41 , January 2003

Modulation of cell death in the tumor microenvironment

References 

  1. Gray LH, Conger AD, Ebert M, et al.  Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638–648
  2. Young SD, Marshall RS, Hill RP. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci U S A. 1988;85:9533–9537
  3. De Jaeger K, Kavanagh MC, Hill RP. Relationship of hypoxia to metastatic ability in rodent tumours. Br J Cancer. 2001;84:1280–1285
  4. Graeber TG, Osmanian C, Jacks T, et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379:88–91
  5. Kim CY, Tsai MH, Osmanian C, et al.  Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res. 1997;57:4200–4204
  6. Rofstad EK, Danielsen T. Hypoxia-induced metastasis of human melanoma cells: Involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer. 1999;80:1697–1707
  7. Royds JA, Dower SK, Qwarnstrom EE, et al.  Response of tumour cells to hypoxia: Role of p53 and NFkB. Mol Pathol. 1998;51:55–61
  8. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol. 2000;35:71–103
  9. Hockel M, Schlenger K, Aral B, et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509–4515
  10. Brizel DM, Sibley GS, Prosnitz LR, et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285–289
  11. Nordsmark M, Alsner J, Keller J, et al.  Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations. Br J Cancer. 2001;84:1070–1075
  12. Semenza GL. Regulation of hypoxia-induced angiogenesis: A chaperone escorts VEGF to the dance. J Clin Invest. 2001;108:39–40
  13. Lartigau E, Le Ridant AM, Lambin P, et al.  Oxygenation of head and neck tumors. Cancer. 1993;71:2319–2325
  14. Martin L, Lartigau E, Weeger P, et al.  Changes in the oxygenation of head and neck tumors during carbogen breathing. Radiother Oncol. 1993;27:123–130
  15. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41:31–39
  16. Kimura H, Braun RD, Ong ET, et al.  Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 1996;56:5522–5528
  17. Brown EB, Campbell RB, Tsuzuki Y, et al.  In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med. 2001;7:864–868
  18. Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol. 2000;76:589–605
  19. Yuan J, Glazer PM. Mutagenesis induced by the tumor microenvironment. Mutat Res. 1998;400:439–446
  20. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol. 2001;28:36–41
  21. Ferrara N, Chen H, Davis-Smyth T, et al.  Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med. 1998;4:336–340
  22. Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer. 1984;49:405–413
  23. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999;15:551–578
  24. Koong AC, Denko NC, Hudson KM, et al.  Candidate genes for the hypoxic tumor phenotype. Cancer Res. 2000;60:883–887
  25. Sowter HM, Ratcliffe PJ, Watson P, et al.  HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 2001;61:6669–6673
  26. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci U S A. 2000;97:9082–9087
  27. Green DR, Evan GI. A matter of life and death. Cancer Cell. 2002;1:19–30
  28. Magnusson KP, Satalino R, Qian W, et al.  Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation?. Oncogene. 1998;17:2333–2337
  29. Kinoshita M, Johnson DL, Shatney CH, et al.  Cancer cells surviving hypoxia obtain hypoxia resistance and maintain anti-apoptotic potential under reoxygenation. Int J Cancer. 2001;91:322–326
  30. Liang BC. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol. 1996;29:149–155
  31. Walenta S, Snyder S, Haroon ZA, et al.  Tissue gradients of energy metabolites mirror oxygen tension gradients in a rat mammary carcinoma model. Int J Radiat Oncol Biol Phys. 2001;51:840–848
  32. Sivitz WI, Lund DD, Yorek B, et al.  Pretranslational regulation of two cardiac glucose transporters in rats exposed to hypobaric hypoxia. Am J Physiol. 1992;263:E562–E569
  33. Firth JD, Ebert BL, Pugh CW, et al.  Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: Similarities with the erythropoietin 3' enhancer. Proc Natl Acad Sci U S A. 1994;91:6496–6500
  34. Semenza GL, Roth PH, Fang HM, et al.  Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994;269:23757–23763
  35. Maxwell PH, Wiesener MS, Chang GW, et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–275
  36. Jaakkola P, Mole DR, Tian YM, et al.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468–472
  37. Ivan M, Kondo K, Yang H, et al.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science. 2001;292:464–468
  38. Williams KJ, Telfer BA, Airley RE, et al.  A protective role for HIF-1 in response to redox manipulation and glucose deprivation: Implications for tumorigenesis. Oncogene. 2002;21:282–290
  39. Seagroves TN, Ryan HE, Lu H, et al.  Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol. 2001;21:3436–3444
  40. Williams KJ, Telfer BA, Airley RE, et al.  A protective role for HIF-1 in response to redox manipulation and glucose deprivation: Implications for tumorigenesis. Oncogene. 2002;21:282–290
  41. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci. 1999;24:68–72
  42. Sutherland R, Freyer J, Mueller-Klieser W, et al.  Cellular growth and metabolic adaptations to nutrient stress environments in tumor microregions. Int J Radiat Oncol Biol Phys. 1986;12:611–615
  43. Koch CJ. Oxygen effects in radiobiology. Adv Exp Med Biol. 1982;157:123–144
  44. Sutherland R, Freyer J, Mueller-Klieser W, et al.  Cellular growth and metabolic adaptations to nutrient stress environments in tumor microregions. Int J Radiat Oncol Biol Phys. 1986;12:611–615
  45. Hochachka PW, Buck LT, Doll CJ, et al.  Unifying theory of hypoxia tolerance: Molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci U S A. 1996;93:9493–9498
  46. Pettersen EO, Juul NO, Ronning OW. Regulation of protein metabolism of human cells during and after acute hypoxia. Cancer Res. 1986;46:4346–4351
  47. Lefebvre VH, Van Steenbrugge M, Beckers V, et al.  Adenine nucleotides and inhibition of protein synthesis in isolated hepatocytes incubated under different pO2 levels. Arch Biochem Biophys. 1993;304:322–331
  48. Hershey JW, Merrick WC. Pathway and mechanism of initiation of protein synthesis. In:  Sonenberg N,  Hershey JW,  Mathews MB editor. Translational control of gene expression. Cold Spring Harbor: Cols Spring Harbor Laboratory Press; 2000;p. 33–88
  49. Koumenis C, Naczki C, Koritzinsky M, et al.  Regulation of protein synthesis by hypoxia via activation of the protein kinase PERK and phosphorylation of elF2alpha. Mol Cell Biol. 2002;22:7405–7416
  50. Koritzinsky M, Koumenis C, Sonenberg N, et al.  Paper presented at the 93rd Annual Meeting of the American Association for Cancer Research, San Francsico, CA, Regulation of protein translation during hypoxic conditions. April 6-10, 2002;
  51. Wouters BG, Weppler SA, Koritzinsky M, et al.  Hypoxia as a target for combined modality treatments. Eur J Cancer. 2002;38:240–257
  52. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 1996;6:10–21
  53. Saunders M, Dische S. Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer. 1996;27:S271–S278 (Suppl)
  54. Overgaard J. Sensitization of hypoxic tumour cells—Clinical experience. Int J Radiat Biol. 1989;56:801–811
  55. Pedersen D, Sogaard H, Overgaard J, et al.  Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. Acta Oncol. 1995;34:787–795
  56. Girinski T, Pejovic-Lenfant MH, Bourhis J, et al.  Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys. 1989;16:37–42
  57. Fein DA, Lee WR, Hanlon AL, et al.  Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol. 1995;13:2077–2083
  58. Lee WR, Berkey B, Marcial V, et al.  Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys. 1998;42:1069–1075
  59. van Acht MJ, Hermans J, Boks DE, et al.  The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol. 1992;23:229–235
  60. Warde P, O'Sullivan B, Bristow RG, et al.  T1/T2 glottic cancer managed by external beam radiotherapy: The influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys. 1998;41:347–353
  61. Dubray B, Mosseri V, Brunin F, et al.  Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology. 1996;201:553–558
  62. Dische S, Warburton MF, Saunders MI. Radiation myelitis and survival in the radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys. 1988;15:75–81
  63. Macchiarini P, Silvano G, Janni A, et al.  Results of treatment and lessons learned from pathologically staged T4 non-small cell lung cancer. J Surg Oncol. 1991;47:209–214
  64. Sasai K, Ono K, Hiraoka M, et al.  The effect of arterial oxygen content on the results of radiation therapy for epidermoid bronchogenic carcinoma. Int J Radiat Oncol Biol Phys. 1989;16:1477–1481
  65. Cole CJ, Pollack A, Zagars GK, et al.  Local control of muscle-invasive bladder cancer: Preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys. 1995;32:331–340
  66. Hannisdal E, Fossa SD, Host H. Blood tests and prognosis in bladder carcinomas treated with definitive radiotherapy. Radiother Oncol. 1993;27:117–122
  67. Wijkstrom H, Nilsson B, Tribukait B. DNA analysis in predicting survival of irradiated patients with transitional cell carcinoma of bladder. Br J Urol. 1992;69:49–55
  68. Greven KM, Solin LJ, Hanks GE. Prognostic factors in patients with bladder carcinoma treated with definitive irradiation. Cancer. 1990;65:908–912
  69. Dunphy EP, Petersen IA, Cox RS, et al.  The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1989;16:1173–1178
  70. Rojas A, Joiner MC, Denekamp J. Extrapolations from laboratory and preclinical studies for the use of carbogen and nicotinamide in radiotherapy. Radiother Oncol. 1992;24:123–124
  71. Chaplin DJ, Horsman MR, Trotter MJ. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J Natl Cancer Inst. 1990;82:672–676
  72. Rojas A. Radiosensitization with normobaric oxygen and carbogen. Radiother Oncol. 1991;1:65–70 (Suppl)
  73. Horsman MR, Nordsmark M, Khalil AA, et al.  Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncol. 1994;33:371–376
  74. Laurence VM, Ward R, Dennis IF, et al.  Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients. Br J Cancer. 1995;72:198–205
  75. Kaanders JH, Pop LA, Marres HA, et al.  Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol. 1998;48:115–122
  76. Bussink J, Kaanders JH. Van der Kogel AJ: Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide. Acta Oncol. 1999;38:875–882
  77. Kaanders JH, Pop LA, Marres HA, et al.  ARCON: Experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:769–778
  78. Hoskin PJ, Saunders MI, Dische S. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer. 1999;86:1322–1328
  79. Bernier J, Denekamp J, Rojas A, et al.  ARCON: Accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC). Radiother Oncol. 2000;55:111–1199
  80. Brown JM, Koong A. Therapeutic advantage of hypoxic cells in tumors: A theoretical study. J Natl Cancer Inst. 1991;83:178–185
  81. Wouters BG, Wang LH, Brown JM. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann Oncol. 1999;10:S29–S33
  82. Brown JM. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer. 1993;67:1163–1170
  83. Lambin P, Theys J, Landuyt W, et al.  Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumors. Anaerobe. 1998;4:183–188
  84. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 1997;57:4537–4544
  85. Lemmon MJ, van Zijl P, Fox ME, et al.  Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 1997;4:791–796
  86. Theys J, Landuyt W, Nuyts S, et al.  Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther. 2001;8:294–297
  87. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186
  88. McNamara DA, Harmey JH, Walsh TN, et al.  Significance of angiogenesis in cancer therapy. Br J Surg. 1998;85:1044–1055
  89. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843–845
  90. Stein I, Neeman M, Shweiki D, Itin A, et al.  Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol. 1995;15:5363–5368
  91. Forsythe JA, Jiang BH, Iyer NV, et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604–4613
  92. Plate KH, Breier G, Millauer B, Ullrich A, Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 1993;53:5822–5827
  93. Fong TA, Shawver LK, Sun L, et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99–106
  94. Laird AD, Vajkoczy P, Shawver LK, et al.  SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000;60:4152–4160
  95. Wood JM, Bold G, Buchdunger E, et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60:2178–2189
  96. Usman N, Blatt LM. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest. 2000;106:1197–1202
  97. Rubenstein JL, Kim J, Ozawa T, et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000;2:306–314
  98. O'Reilly MS:. Angiostatin: An endogenous inhibitor of angiogenesis and of tumor growth. Exs. 1997;79:273–294
  99. O'Reilly MS, Boehm T, Shing Y, et al.  Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277–285
  100. Figg WD, Dahut W, Duray P, et al.  A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001;7:1888–1893
  101. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407–424
  102. Min HY, Doyle LV, Vitt CR, et al.  Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996;56:2428–2433
  103. Li H, Lu H, Griscelli F, et al.  Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther. 1998;5:1105–1113
  104. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest. 1999;103:1227–1230
  105. Reynolds LE, Wyder L, Lively JC, et al.  Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002;8:27–34
  106. Carmeliet P. Integrin indecision. Nat Med. 2002;8:14–16
  107. Yu JL, Rak JW, Coomber BL, et al.  Effect of p53 status on tumor response to antiangiogenic therapy. Science. 2002;295:1526–1528
  108. Kerbel RS, Yu J, Tran J, et al.  Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev. 2001;20:79–86
  109. Yu JL, Rak JW, Carmeliet P, et al.  Heterogeneous vascular dependence of tumor cell populations. Am J Pathol. 2001;158:1325–1334
  110. Zundel W, Schindler C, Haas-Kogan D, et al.  Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000;14:391–396
  111. Zhong H, Chiles K, Feldser D, et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res. 2000;60:1541–1545
  112. Chang EH, Miller PS, Cushman C, et al.  Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry. 1991;30:8283–8286
  113. Feng M, Cabrera G, Deshane J, et al.  Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res. 1995;55:2024–2028
  114. Richardson JH, Marasco WA. Intracellular antibodies: Development and therapeutic potential. Trends Biotechnol. 1995;13:306–310
  115. Izumi Y, Xu L, di Tomaso E, et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature. 2002;416:279–280
  116. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002;29:27–36
  117. Eastham JA, Hall SJ, Sehgal I, et al.  In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 1995;55:5151–5155
  118. Roth JA, Nguyen D, Lawrence DD, et al.  Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996;2:985–991
  119. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7:228–234
  120. Chen YN, Sharma SK, Ramsey TM, et al.  Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A. 1999;96:4325–4329

☆ Address reprint requests to Bradly G. Wouters, PhD, Department of Experimental Radiation Oncology, UNS 50/Box 23, azM/University of Maastricht, Postbox 616, 6200 MD Maastricht, The Netherlands.

PII: S1053-4296(03)50006-6

doi: 10.1053/srao.2003.50004

Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 31-41 , January 2003

Article Tools

* Image Usage & Resolution